2
|
Schenck L, Patel P, Sood R, Bonaga L, Capella P, Dirat O, Erdemir D, Ferguson S, Gazziola C, Gorka LS, Graham L, Ho R, Hoag S, Hunde E, Kline B, Lee SL, Madurawe R, Marziano I, Merritt JM, Page S, Polli J, Ramanadham M, Sapru M, Stevens B, Watson T, Zhang H. FDA/M-CERSI Co-Processed API Workshop Proceedings. J Pharm Sci 2023:S0022-3549(23)00007-2. [PMID: 36638959 DOI: 10.1016/j.xphs.2023.01.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Revised: 01/05/2023] [Accepted: 01/05/2023] [Indexed: 01/11/2023]
Abstract
These proceedings contain presentation summaries and discussion highlights from the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) Workshop on Co-processed API, held on July 13 and 14, 2022. This workshop examined recent advances in the use of co-processed active pharmaceutical ingredients as a technology to improve drug substance physicochemical properties and drug product manufacturing process robustness, and explored proposals for enabling commercialization of these transformative technologies. Regulatory considerations were discussed with a focus on the classification, CMC strategies, and CMC documentation supporting the use of this class of materials from clinical studies through commercialization. The workshop format was split between presentations from industry, academia and the FDA, followed by breakout sessions structured to facilitate discussion. Given co-processed API is a relatively new concept, the authors felt it prudent to compile these proceedings to gain further visibility to topics discussed and perspectives raised during the workshop, particularly during breakout discussions. Disclaimer: This paper reflects discussions that occurred among stakeholder groups, including FDA, on various topics. The topics covered in the paper, including recommendations, therefore, are intended to capture key discussion points. The paper should not be interpreted to reflect alignment on the different topics by the participants, and the recommendations provided should not be used in lieu of FDA published guidance or direct conversations with the Agency about a specific development program. This paper should not be construed to represent FDA's views or policies.
Collapse
Affiliation(s)
- Luke Schenck
- Process Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
| | - Paresma Patel
- Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States
| | - Ramesh Sood
- Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States
| | - Llorente Bonaga
- CMC Pharmaceutical Development and New Products, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Peter Capella
- Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States
| | - Olivier Dirat
- Global Regulatory CMC, Global Product Development, Pfizer R&D UK Ltd, Sandwich, CT13 9NJ, United Kingdom
| | - Deniz Erdemir
- Drug Product Development, Bristol-Myers Squibb, 1 Squibb Drive, New Brunswick New Jersey 08903, United States
| | - Steven Ferguson
- SSPC, the SFI Research Centre for Pharmaceuticals, School of Chemical and Bioprocess Engineering, University College Dublin, Belfield, Dublin 4. & National Institute for Bioprocess Research and Training, 24 Foster's Ave, Belfield, Blackrock, Co. Dublin, A94 × 099, Ireland
| | - Cinzia Gazziola
- Technical Regulatory Affairs, F. Hoffmann-La Roche Ltd, Roche Basel, CH-4051, Basel, Switzerland
| | | | - Laurie Graham
- Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States
| | - Raimundo Ho
- Small Molecule CMC Development, AbbVie Inc., 1 N Waukegan Road, North Chicago, IL 60064, United States
| | - Stephen Hoag
- Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland 21201, United States
| | - Ephrem Hunde
- Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States
| | - Billie Kline
- Engineering and Materials Sciences, Vertex Pharmaceuticals, 50 Northern Avenue, Boston, MA 02210, United States
| | - Sau Larry Lee
- Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States
| | - Rapti Madurawe
- Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States
| | - Ivan Marziano
- Chemical Research and Development, Pfizer R&D UK Ltd, Sandwich, CT13 9NJ, United Kingdom
| | - Jeremy Miles Merritt
- Synthetic Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46221, United States
| | - Sharon Page
- Global Regulatory CMC, Global Product Development, Pfizer R&D UK Ltd, Sandwich, CT13 9NJ, United Kingdom
| | - James Polli
- Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland 21201, United States
| | - Mahesh Ramanadham
- Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States
| | - Mohan Sapru
- Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, 10903 New Hampshire Ave, Silver Spring, MD 20993, United States
| | - Ben Stevens
- CMC Policy and Advocacy, Global CMC Regulatory Affairs, GSK, 1250 S. Collegeville Rd, Collegeville, PA 19426, United States
| | - Tim Watson
- Global Regulatory CMC, Global Product Development, Pfizer Inc., Groton, CT 06340
| | - Haitao Zhang
- Chemical Process R&D, Sunovion Pharmaceuticals Inc., 84 Waterford Drive, Marlborough MA, 01752 USA
| |
Collapse
|